Physician profile
J Carvel Jackson
NPI 1942262399
$2,646.54
in general payments reported to CMS, 2019-2025
13 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 90% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.10 · 2020: $61.27 · 2021: $88.13 · 2022: $27.10 · 2023: $152 · 2024: $966 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,625 · Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,625.00 |
| Food and Beverage | $767.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $1,946.22 | 2024-2025 | Roxybond |
| Braeburn INC. | $177.26 | 2023-2025 | Brixadi |
| Dermavant Sciences, INC. | $114.08 | 2023-2024 | Vtama |
| Alkermes, INC. | $114.02 | 2021-2023 | Vivitrol |
| Mdd US Operations, LLC | $68.76 | 2019-2020 | |
| Indivior INC. | $45.00 | 2019-2020 | |
| Organogenesis INC. | $38.82 | 2025 | Puraply Wound Matrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.24 | 2024-2025 | Relistor |
| Uswm, LLC | $31.92 | 2021 | |
| Orexo US, INC. | $24.61 | 2019-2021 | |
| Janssen Biotech, INC. | $24.11 | 2023 | Tremfya |
| Leo Pharma INC. | $17.87 | 2025 | Adbry |
| Titan Pharmaceuticals, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Carvel Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.